	US 12,221,479 B2
	Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies
Jörg Willuda, Glienicke/Nordbahn (DE); Mark Trautwein, Wülfrath (DE); Rienk Offringa, Heidelberg (DE); Hans-Henning Böhm, Heidelberg (DE); and Philipp Beckhove, Heidelberg (DE)
Assigned to Bayer Aktiengesellschaft, Leverkusen (DE); and Deutsches Krebsforschungszentrum, Heidelberg (DE)
Appl. No. 17/416,958
Filed by Bayer Aktiengesellschaft, Leverkusen (DE); and Deutsches Krebsforschungszentrum, Heidelberg (DE)
PCT Filed Dec. 12, 2019, PCT No. PCT/EP2019/084849 § 371(c)(1), (2) Date Jun. 21, 2021, PCT Pub. No. WO2020/126808, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 18214059 (EP), filed on Dec. 19, 2018.
Prior Publication US 2022/0089721 A1, Mar. 24, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)]

11 Claims

1. A method of treating cancer comprising administering anti-CEACAM6 antibody before, after or with an effective amount of an anti-TIM-3 antibody in the treatment of cancer,

wherein the cancer to be treated expresses CEACAM6,

wherein the anti-CEACAM6 antibody comprises H-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, H-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, H-CDR3 comprising the amino acid sequence of SEQ ID NO: 4, L-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, L-CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and L-CDR3 comprising the amino acid sequence of SEQ ID NO: 8.